Crystal structure of (S)-4-(2-(4-(2-acetyl-5-chlorophenyl)-3-methoxy-6-oxopyridazin-1(6H)-yl)-3-phenylpropanamido)benzoic acid monohydrate, C29H26ClN3O7-Reference-Cited by-同舟云学术

Crystal structure of (S)-4-(2-(4-(2-acetyl-5-chlorophenyl)-3-methoxy-6-oxopyridazin-1(6H)-yl)-3-phenylpropanamido)benzoic acid monohydrate, C₂₉H₂₆ClN₃O₇

Published:2024-07-31 Issue:5 Volume:239 Page:945-947
ISSN:1433-7266
Container-title:Zeitschrift für Kristallographie - New Crystal Structures
language:en
Short-container-title:

Author:

Wen-Jie Xu¹,Ying Xiao¹,Duan-Ming Tan¹,Song Li¹^ORCID

Affiliation:

1. Shenzhen Salubris Pharmaceuticals Co., Ltd , Shenzhen 518118 , People’s Republic of China

Abstract

Abstract C29H26ClN3O7, monoclinic, P21 (no. 4), a = 15.5488(6) Å, b = 7.9366(3) Å, c = 22.6498(9) Å, β = 93.006(2)°, V = 2,791.24(19) Å3, Z = 4, R gt (F) = 0.0528, wR ref (F 2) = 0.1391, T = 292 K.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/ncrs-2024-0246/pdf

Reference8 articles.

1. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.

2. Sheldrick, G. M. SHELXTL – Integrated Space-Group and Crystal-Structure Determination. Acta Crystallogr. 2015, A71, 3–8.

3. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.

4. Wei, Q.; Zheng, Z.; Zhang, S.; Zheng, X.; Meng, F.; Yuan, J.; Xu, Y.; Huang, C. Fragment-Based Lead Generation of 5-Phenyl-1h-Pyrazole-3-Carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors. Molecules 2018, 23, 2002; https://doi.org/10.3390/molecules23082002.

5. Al-Horani, R. A.; Afosah, D. K. Recent Advances in the Discovery and Development of Factor XI/XIa Inhibitors. Med. Res. Rev. 2018, 38, 1974–2023; https://doi.org/10.1002/med.21503.